“…The application of spirocycles to drug discovery efforts has increased in recent years as a means to increase compound three-dimensionality, modulate DMPK properties, incorporate additional sp 3 centers, and generate novel intellectual property. − One of the central findings of the present study was the discovery of 2,7-diazaspiro[3.5]nonane as an applicable core motif for selective D 4 R antagonists. While we initially identified the highly potent antagonist VU6052469 , which exhibited a high degree of structural similarity to a previously reported selective D 4 R antagonist, it notably lacked selectivity (Figure B,D,E). We postulated that this lack of selectivity arose from the difference in length between these two compounds, with the naphthalene and 4-chlorobenzyl moieties of the Carato compound potentially leading to poorer steric interactions within the TM2/3 pocket of D 2 R than the dimethylphenyl and 3,4-difluorobenzyl moieties of VU6052469 (Figure E).…”